Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

References

• The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network; 2018.
   Google Scholar
• Martinez FD, Vercelli D. Asthma. Lancet. 2013;382:1360–1372.
   PubMed Web of Science ®Google Scholar
• Gould H, Sutton B, Beavil A, et al. The biology of IGE and the basis of allergic disease. Annu Rev Immunol. 2003;21:579–628.
   PubMed Web of Science ®Google Scholar
• Shin JS, Greer AM. The role of FcεRI expressed in dendritic cells and monocytes. Cell Mol Life Sci. 2015;72(12):2349–2360.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042.
   PubMed Web of Science ®Google Scholar
• Storms W. Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy. Am J Respir Med. 2002;1(5):361–368.
   PubMedGoogle Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828–1834.
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378–1386.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE anti- body omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261.
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002;20:1088–1094.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Neffen H, Castro-Rodriguez J. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35.
   PubMed Web of Science ®Google Scholar
• D’Amato G, Bucchioni E, Oldani V, et al. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (omalizumab). Treat Respir Med. 2006;5:392–398.
   Google Scholar
• D’Amato G, Perticone M, Bucchioni E, et al. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab) An update. Eur Ann Allergy Clin Immunol. 2010;42:135–140.
   PubMedGoogle Scholar
• Holgate S, Buhl R, Bousquet J, et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103:1098–1113.
   PubMed Web of Science ®Google Scholar
• Kuhl K, Hanania N. Targeting IgE in asthma. Curr Opin Pulm Med. 2012;18:1–5.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy. 2011;4:49–59.
   PubMedGoogle Scholar
• Menzies-Gow A, Fan Chung K. Omalizumab for the treatment of severe allergic asthma. Expert Rev Clin Immunol. 2008;4:543–548.
   PubMed Web of Science ®Google Scholar
• Babu K, Arshad S, Holgate S. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin Biol Ther. 2001;1:1049–1058.
   PubMed Web of Science ®Google Scholar
• Ledford D. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther. 2009;9:933–943.
   PubMed Web of Science ®Google Scholar
• Corren J, Casala T, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788–797.
   PubMed Web of Science ®Google Scholar
• Tan R, Corren J. Safety of omalizumab in asthma. Expert Opin Drug Saf. 2011;10:463–471.
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med. 2008;102:71–76. .
   PubMed Web of Science ®Google Scholar
• Brusselle G, Michils A, Louis R, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633–1642.
   PubMed Web of Science ®Google Scholar
• Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103:1725–1731.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410–1416.
   PubMed Web of Science ®Google Scholar
• Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105:313–319.
   PubMed Web of Science ®Google Scholar
• Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104:1381–1385.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66:671–678.
   PubMed Web of Science ®Google Scholar
• Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011;180:637–641.
   PubMed Web of Science ®Google Scholar
• Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49:78–82.
   PubMed Web of Science ®Google Scholar
• Rubin S, Souza-Machado A, Andradre-Lima M, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49:288–293.
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012;6:215–227.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Brightling CE, Menzies-Gow A, et al. Clinical management and outcome of refractory asthma in the UK from the British thoracic society difficult asthma registry. Thorax. 2012;67:754–756.
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omalizumab treatment in severe allergic asthma: the south-eastern Mediterranean “real-life” experience. Pulm Pharmacol Ther. 2012;25:77–82.
   PubMed Web of Science ®Google Scholar
• Vennera Mdel C, Pérez de Llano L, Bardagí S, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry — some new approaches. J Asthma. 2012;49:416–422.
   PubMed Web of Science ®Google Scholar
• Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50:529–536.
   PubMed Web of Science ®Google Scholar
• Braunstahl G, Chlumský J, Peachey G, et al. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol. 2013;9:47.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Zureik M, Aubier M, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143:398–405.
   PubMed Web of Science ®Google Scholar
• Kelmenson DA, Kelly VJ, Winkler T, et al. The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. Am J Nucl Med Mol Imaging. 2013;3:350–360.
   PubMedGoogle Scholar
• Subramaniam A, Al-Alawi M, Hamad S, et al. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral center for asthma in Ireland. QJM. 2013;106:631–634.
   PubMed Web of Science ®Google Scholar
• Alfarroba S, Videira W, Galvão-Lucas C, et al. Clinical experience with omalizumab in a Portuguese severe asthma unit. Rev Port Pneumol. 2014;20:78–83.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113:470–475.
   PubMed Web of Science ®Google Scholar
• Vieira T, Oliveira J, Castel-Branco M. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol (Madr). 2014;42:3–10.
   PubMed Web of Science ®Google Scholar
• Novelli F, Latorre M, Vergura L, et al. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–129.
   PubMed Web of Science ®Google Scholar
• Tiro J, Contreras E, Pozo M, et al. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr). 2015;43:120–126.
   PubMed Web of Science ®Google Scholar
• Abraham I, Alhossan A, Lee CS, et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71:593–610.
   PubMed Web of Science ®Google Scholar
• Alhossan A, Lee CS, MacDonald K, et al. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.
   PubMed Web of Science ®Google Scholar
• Zazzali JL, Raimundo KP, Trzaskoma B, et al. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc. 2015;36:283–292.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444.
   PubMed Web of Science ®Google Scholar
• Tortajada-Girbés M, Bousquet R, Bosque M, et al. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. Expert Rev Resp Med. 2018;12(9):745–754. .
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence. Expert Opin Biol Ther. 2018;18(4):425–448.
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2018;155(1):29–38.
   Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Canvin J, Peachey G, et al. Healthcare resource utilization in patients receiving omalizumab for allergic asthma in a real-world setting. Biol Ther. 2014;4(1–2):57–67.
   PubMedGoogle Scholar
• Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49:843–848.
   PubMed Web of Science ®Google Scholar
• Wittchen H-U, Mühlig S, Klotsche J, et al. Omalizumab versus ‘usual care’: results from a naturalistic longitudinal study in routine care. Int Arch Allergy Immunol. 2012;159:83–93.
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Chieco Bianchi F, et al. Omalizumab management beyond clinical trials: the added value of a network model. Pulm Pharmacol Ther. 2014;29(1):74–79.
   PubMed Web of Science ®Google Scholar
• Gouder C, West LM, Montefort S. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm. 2015;37(1):36–43.
   PubMed Web of Science ®Google Scholar
• Kupryś-Lipińska I, Majak P, Molinska J, et al. Effectiveness of the polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016;16(1):61.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Latorre M, et al. Effects of omalizumab in severe asthmatics across ages: a real life Italian experience. Respir Med. 2016;119:141–149.
   PubMed Web of Science ®Google Scholar
• Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Ann Allergy Asthma Immunol. 2016;117(5):546–549.
   PubMed Web of Science ®Google Scholar
• de Carvalho-Pinto RM, Agondi RC, Giavina-Bianchi P, et al. Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control. J Bras Pneumol. 2017;43(6):487–489.
   PubMed Web of Science ®Google Scholar
• Mansur AH, Srivastava S, Mitchell V, et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir Med. 2017;124:36–43.
   PubMed Web of Science ®Google Scholar
• Nygaard L, Henriksen DP, H M, et al. Appropriate selection for omalizumab treatment in patients with severe asthma? Eur Clin Respir J. 2017;4(1):1359477.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Romeo P, et al. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther. 2011;49(12):713–721.
   PubMed Web of Science ®Google Scholar
• Özgür ES, Özge C, Ïlvan A, et al. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma. J Asthma. 2013;50(6):687–694.
   PubMed Web of Science ®Google Scholar
• Ancochea J, Chivato T, Casan P, et al. Profile of patients treated with omalizumab in routine clinical practice in Spain. Allergol Immunopathol (Madr). 2014;42(2):102–108.
   PubMed Web of Science ®Google Scholar
• Niven RM, Saralaya D, Chaudhuri R, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016;6(8):e011857.
   PubMed Web of Science ®Google Scholar
• DiBona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Resp Med. 2017;130:55–60.
   PubMed Web of Science ®Google Scholar
• Kawamatawong T, Poachanukoon O, Boonsiri C, et al. Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience. Asian Pac J Allergy Immunol. 2017 Nov 22. DOI:10.12932/AP0872
   Web of Science ®Google Scholar
• Maltby S, Gibson PG, Powell H, et al. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151(1):78–89.
   PubMed Web of Science ®Google Scholar
• Paganin F, Mangiapan G, Proust A, et al. Lung function parameters in omalizumab responder patients: an interesting tool? Allergy. 2017;72(12):1953–1961.
   PubMed Web of Science ®Google Scholar
• Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Resp Med. 2018;141:56–63. .
   PubMed Web of Science ®Google Scholar
• Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016 Sep;46(9):1054–1062.
   PubMed Web of Science ®Google Scholar
• Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Resp Dis. 2012;6(2):87–95.
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. .
   PubMed Web of Science ®Google Scholar
• Storms W, Bowdish MS, Farrar JR. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. Allergy Asthma Proc. 2012;33:172–177. .
   PubMed Web of Science ®Google Scholar
• Bhutani M, Yang WH, Hébert J, et al. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX observational study. PloS One. 2017;12(8):e0183869.
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2018 May 22. pii: S2213-2198(18)30323-4. DOI:10.1016/j.jaip.2018.04.043
   Web of Science ®Google Scholar
• Ohta K, Yamamoto M, Sato N, et al. One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma. Allergol Int. 2010;59(2):167–174.
   PubMedGoogle Scholar
• Pilon D, Kavati A, Ortiz B, et al. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma. Allergy Asthma Proc. 2018;39(2):127–135.
   PubMed Web of Science ®Google Scholar
• Chen HC, Huang CD, Chang E, et al. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med. 2016;16:3.
   PubMed Web of Science ®Google Scholar
• Chen H, Eisner MD, Haselkorn T, et al. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013;107(1):60–67.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Singh H, Diaz J, et al. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study. Ann Allergy Asthma Immunol. 2013;110(6):457–461.
   PubMed Web of Science ®Google Scholar